Worth reading
51Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
215
¥100 million (year-on-year increase in revenue)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ended March 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales1,295 Hundred millions of yen+19.9%
Operating profit182 Hundred millions of yen-10.8%
Ordinary income¥183 100 million +53.3%profit before tax for the quarter
Net income¥170 100 million +51.7%profit for the quarter attributable to owners of the parent
Gross Profit Margin52.6% (¥68.1 billion ÷ ¥129.5 billion)
Operating profit margin14.1% (¥18.2 billion ÷ ¥129.5 billion)
Selling, general and administrative expenses392 Hundred millions of yen
Results for the three months of the current quarterThe standalone results for the three months of the first quarter of FY2026 were revenue of ¥129.5 billion, operating profit of ¥18.2 billion, profit before tax for the quarter of ¥18.3 billion, and profit for the quarter attributable to owners of the parent of ¥17.0 billion.
Full-year earnings forecast
Revenue
5,400 Hundred millions of yen
Gross profit
2,950 Hundred millions of yen
Core operating profit
910 Hundred millions of yen
Operating profit
900 Hundred millions of yen
Profit for the period attributable to owners of the parent
770 Hundred millions of yen
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Revenue by region
Japan25.4%
United States23.2%
Other28.2%
Total24.0%
Key productsPresented by product
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue
Japan10 Hundred millions of yen
United States244 Hundred millions of yen
Other-39 Hundred millions of yen
Operating profit-related items
Cost of sales173 Hundred millions of yen
Selling, general and administrative expenses36 Hundred millions of yen
Research and development costs33 Hundred millions of yen
Profit before tax-related items
Financial Expenses-70 Hundred millions of yen
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Assumed average JPY/USD exchange rate155 JPY/USD
Foreign exchange sensitivity
Impact on revenue of a ¥1 depreciation of the yen28 Hundred millions of yen
Impact on core operating profit of a ¥1 depreciation of the yen6 Hundred millions of yen
New initiatives
- Updates to the development pipeline
- In March 2026, conditional and time-limited approval was obtained in Japan for アムシェプリ (ラグネプロセル), a regenerative cell therapy.
- Research and development of regenerative and cell therapies using iPS cells continues with RACTHERA and others.
Key KPIsA metric the company considers important as a management benchmark.
- Overseas Revenue Mix82.8 %Year on year against the same period last year80.5% in the same period of the previous year
- Basic earnings per share¥39.02Same-period previous-year figure28.21
Segment results
Revenue by region
Japan
222 Hundred millions of yen+4.6%
United States
943 Hundred millions of yen+34.9%
Other
130 Hundred millions of yen-22.9%
Gross profit by region
Japan
97 Hundred millions of yen
United States
570 Hundred millions of yen
Other
13 Hundred millions of yen
Financial targets
ROE
Actual results46.3 %
Full-year forecast20.3 %
ROIC
Actual results22.8 %
Full-year forecast15.1 %
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ended March 2026 |
| Net Sales | 1,295 Hundred millions of yen (YoY +19.9%) |
| Operating profit | 182 Hundred millions of yen (YoY -10.8%) |
| Ordinary income | ¥183 100 million (profit before tax for the quarter) (YoY +53.3%) |
| Net income | ¥170 100 million (profit for the quarter attributable to owners of the parent) (YoY +51.7%) |
| Gross Profit Margin | 52.6% (¥68.1 billion ÷ ¥129.5 billion) |
| Operating profit margin | 14.1% (¥18.2 billion ÷ ¥129.5 billion) |
| Selling, general and administrative expenses | 392 Hundred millions of yen |
| Results for the three months of the current quarter | The standalone results for the three months of the first quarter of FY2026 were revenue of ¥129.5 billion, operating profit of ¥18.2 billion, profit before tax for the quarter of ¥18.3 billion, and profit for the quarter attributable to owners of the parent of ¥17.0 billion. |
| Full-year earnings forecast | Revenue 5,400 Hundred millions of yen / Gross profit 2,950 Hundred millions of yen / Core operating profit 910 Hundred millions of yen / Operating profit 900 Hundred millions of yen / Profit for the period attributable to owners of the parent 770 Hundred millions of yen |
| Progress against full-year forecast | Revenue by region Japan 25.4% / United States 23.2% / Other 28.2% / Total 24.0% / Key products Presented by product |
| Segment results | Revenue by region Japan 222 Hundred millions of yen (YoY +4.6%) / United States 943 Hundred millions of yen (YoY +34.9%) / Other 130 Hundred millions of yen (YoY -22.9%) / Gross profit by region Japan 97 Hundred millions of yen / United States 570 Hundred millions of yen / Other 13 Hundred millions of yen |
| Breakdown of Factors Affecting the Change | Revenue Japan 10 Hundred millions of yen / United States 244 Hundred millions of yen / Other -39 Hundred millions of yen / Operating profit-related items Cost of sales 173 Hundred millions of yen / Selling, general and administrative expenses 36 Hundred millions of yen / Research and development costs 33 Hundred millions of yen / Profit before tax-related items Financial Expenses -70 Hundred millions of yen |
| Key KPIs | Indicator name Overseas Revenue Mix / Value 82.8 % / Year on year against the same period last year 80.5% in the same period of the previous year, Indicator name Basic earnings per share / Value ¥39.02 / Same-period previous-year figure ¥28.21 |
| Assumptions Underlying the Business Outlook | Assumed average JPY/USD exchange rate 155 JPY/USD / Foreign exchange sensitivity Impact on revenue of a ¥1 depreciation of the yen 28 Hundred millions of yen / Impact on core operating profit of a ¥1 depreciation of the yen 6 Hundred millions of yen |
| Financial targets | ROE Actual results 46.3 % / Full-year forecast 20.3 % / ROIC Actual results 22.8 % / Full-year forecast 15.1 % |
| New initiatives | Updates to the development pipeline, In March 2026, conditional and time-limited approval was obtained in Japan for アムシェプリ (ラグネプロセル), a regenerative cell therapy., Research and development of regenerative and cell therapies using iPS cells continues with RACTHERA and others. |
Items this document does not state (13)
Self-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The numerical factors cited by the company were increases of ¥24.4 billion in U.S. sales and ¥1.0 billion in sales in Japan, a ¥3.9 billion decline in sales in other regions, and foreign exchange effects of ¥8.9 billion in the United States and ¥0.7 billion in other regions. With respect to operating profit, cost of sales increased by ¥17.3 billion, selling, general and administrative expenses by ¥3.6 billion, and research and development expenses by ¥3.3 billion. The ¥7.0 billion decrease in finance costs contributed to the increase in profit before tax.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.